Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval
Open accessPublished version of a preprint
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Despite strong vetting for disease activity, only 10% of candidate new molecular entities in early stage clinical trials are eventually approved. Analyzing historical pipeline data, Nelson et al. 2015 (Nat. Genet.) concluded pipeline drug targets with human genetic evidence of disease association are twice as likely to lead to approved drugs. Taking advantage of recent clinical development advances and rapid growth in GWAS datasets, we extend the original work using updated data, test whether genetic evidence predicts future successes and introduce statistical models adjusting for target and indication-level properties. Our work confirms drugs with genetically supported targets were more likely to be successful in Phases II and III. When causal genes are clear (Mendelian traits and GWAS associations linked to coding variants), we find the use of human genetic evidence increases approval by greater than two-fold, and, for Mendelian associations, the positive association holds prospectively. Our findings suggest investments into genomics and genetics are likely to be beneficial to companies deploying this strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 Estimated effect of evidence from human genetic studies on the probability of advancing in clinical development. A: Partitioning Pharmaprojects, OMIM, and GWAS Catalog into training data available to Nelson et al. 2015 and validation sets. We use validation set Pipeline Progression, consisting of target-indication pairs assigned a clinical phase in 2013, to determine whether gene target-indication pairs with genetic evidence were more likely to advance to the next pipeline phase from 2013-2018. Pharmaprojects target-indication pairs absent from or assigned an unknown clinical phase in the Nelson et al. dataset form the New Pipeline replication set. Pharmaprojects target-indication pairs approved prior to 2013 or with unknown phase in our dataset are not part of any replication set. B: Our estimates of the effect of genetic evidence on gene target-indication pair progression compared to values reported by Nelson et al. 2015 [3] in validation sets New Pipeline (drugs and indications > 2013, 2013 inactive drugs) New Genetic (only new genetic information > 2013) Pipeline Progression, and in the full updated dataset (Full Data). Estimates falling close to the identity line (shown in black) are consistent between the two analyses.](https://figures.cochat.ai/paper-figures/fbfe5599a9364dd7aab42f07a9e12b6a/are-drug-targets-with-genetic-support-twice-as-likely-to-be-approved-revised-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is supported by drug candidates with genetically supported targets being significantly more likely to progress through phased clinical trials (9, 10).”
From Identification of human gene research articles with wrongly identified nucleotide sequences (2022) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans
The GTEx Consortium, Ardlie, K. G., Deluca, D. S., Segrè, A. V., Sullivan, T. J., Young, T. R., Gelfand, E. T., Trowbridge, C. A., Maller, J. B., Tukiainen, T., et al. (2015) · Science · doi:10.1126/science.1262110 · Cited by 5,062
An Information-Theoretic Definition of Similarity
Lin, D. (1998) · International Conference on Machine Learning · Cited by 4,697
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
The NHGRI GWAS Catalog, a curated resource of SNP-trait associations
Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A., Flicek, P., Manolio, T., Hindorff, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1229 · Cited by 2,707
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Watanabe, S. (2010) · arXiv (Cornell University) · doi:10.48550/arxiv.1004.2316 · Cited by 2,226
Research works printed but not linked: 1
- J MacArthur, 2016, The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog), Nucleic Acids Research, 45, D896, 10.1093/nar/gkw1133 · DOI · Paper page
Cited by
Items 301–400 of 648
Stratford, J. K., Carnes, M. U., Willis, C., Minto, M. S., Elnimeiry, L., Mathur, R., Schu, M. C., Quach, B. C., Carter, J. K., Nolen, T. L., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03721-9 · Cited by 8
He, Z., Chu, B. B., Yang, J., Gu, J., Chen, Z., Liu, L., Morrison, T., Belloy, M. E., Qi, X., Hejazi, N., et al. (2026) · Genome biology · doi:10.1186/s13059-026-04185-w · Cited by 8
Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders
Trajanoska, K., & Rivadeneira, F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.556610 · Cited by 9
Using “-omics” Data to Inform Genome-wide Association Studies (GWASs) in the Osteoporosis Field
Abood, A., & Farber, C. R. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00684-w · Cited by 8
West, C. E., Karim, M. A., Falaguera, M. J., Speidel, L., Green, C., Logie, L., Schwartzentruber, J., Ochoa, D., Lord, J. M., Ferguson, M. A. J., et al. (2023) · Scientific Data · doi:10.1038/s41597-023-02513-4 · Cited by 9
Somineni, H., Mukherjee, S., Amar, D., Pei, J., Guo, K., Light, D., Flynn, K. J., Probert, C. S., Soare, T. W., Satapati, S., et al. (2024) · medRxiv · doi:10.1101/2024.01.06.24300923 · Cited by 9
The impact on clinical success from the 23andMe cohortPreprint
Wang, X., Karagounis, S., Shringarpure, S., Srivas, R., Su, Q. J., Vacic, V., Pitts, S. J., & Auton, A. (2024) · medRxiv · doi:10.1101/2024.06.17.24309059 · Cited by 9
Human genetics guides the discovery of CARD9 inhibitors with anti-inflammatory activity
Rush, J. S., Wertheimer, J. D., Goldberg, S. D., Raymond, D. D., Szuchnicki, M., Baltus, A. J., Branson, J., Stratton, C. F., Patrick, A. N., Steele, R. A., et al. (2026) · Cell · doi:10.1016/j.cell.2025.12.013 · Cited by 8
Hu, J., Luo, Y., & Wang, X. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100128 · Cited by 10
Rahimov, F., Ghosh, S., Petiwala, S. M., Schmidt, M., Nyamugenda, E., Shi, M., Tam, J. W., Verduzco, D., Singh, S., Avram, V., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65277-y · Cited by 7
Temporal trends in evidence supporting novel drug target discovery
Falaguera, M. J., McDonagh, E. M., Ochoa, D., Rusina, P. V., Roldán‐Romero, J. M., Hulcoop, D. G., Leach, A. R., & Dunham, I. (2025) · Nature Communications · doi:10.1038/s41467-025-67180-y · Cited by 12
CDx, NGS and regulation: five perspectives from the Pistoia Alliance
Wise, J. A., Furness, M., McWilliams, S., & Patton, S. J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.07.002 · Cited by 7
Functional genomics, genetic risk profiling and cell phenotypes in neurodegenerative disease
Finkbeiner, S. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105088 · Cited by 9
Raghavachari, N., Wilmot, B., & Dutta, C. (2022) · The Journals of Gerontology Series A · doi:10.1093/gerona/glac065 · Cited by 7
Poppelaars, F., da Costa, M. G., Faria, B., Eskandari, S. K., Seelen, M. A., & Damman, J. J. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s334738 · Cited by 8
Lee, I., Walker, D. I., Lin, Y., Smith, M. R., Mandl, K. D., Jones, D. P., & Kong, S. W. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104746 · Cited by 11
Drug repurposing opportunities for chronic kidney disease
Chen, X., Shen, R., Zhu, D., Luo, S., You, G., Li, R., Hong, X., Li, R., Wu, J., Huang, Y., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109953 · Cited by 7
Heikkilä, T. E., Kaiser, E., Lin, J., Gill, D., Koskenniemi, J. J., & Karhunen, V. (2024) · Diabetologia · doi:10.1007/s00125-024-06267-5 · Cited by 7
Germline mechanisms of immunotherapy toxicities in the era of genome‐wide association studies
Gusev, A. (2023) · Immunological Reviews · doi:10.1111/imr.13253 · Cited by 8
SMIM1 absence is associated with reduced energy expenditure and excess weight
Stefanucci, L., Moslemi, C., Tomé, A. R., Virtue, S., Bidault, G., Gleadall, N., Watson, L. P. E., Kwa, J. E., Burden, F., Farrow, S., et al. (2024) · Med · doi:10.1016/j.medj.2024.05.015 · Cited by 9
Hazelwood, E., Canson, D. M., Deslandes, B., Wang, X. M., Kho, P. F., Legge, D., Constantinescu, A., Lee, M. A., Bishop, D. T., Chan, A. T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60275-6 · Cited by 9
The gene expression landscape of disease genes
García‐González, J., Cote, A. C., Garcia-Gonzalez, S., Liou, L., & O’Reilly, P. F. (2026) · Genome biology · doi:10.1186/s13059-026-03958-7 · Cited by 7
Taylor‐Bateman, V., Bothongo, P. L., Walker, V. M., Kehoe, P. G., Nordestgaard, L. T., Ben‐Shlomo, Y., Davies, N. M., Williams, D. M., & Anderson, E. L. (2026) · Nature Aging · doi:10.1038/s43587-026-01106-1 · Cited by 6
Lee, H. K., Kwon, D. H., Aylor, D. L., & Marchuk, D. A. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.09.003 · Cited by 6
Predicting ExWAS findings from GWAS data: a shorter path to causal genes
Liang, K. Y. H., Farjoun, Y., Forgetta, V., Chen, Y., Yoshiji, S., Lu, T., & Richards, J. B. (2023) · Human Genetics · doi:10.1007/s00439-023-02548-y · Cited by 6
Utilizing Human Genetics to Develop Chemoprevention for Cancer—Too Good an Opportunity to be Missed
Peters, U., & Tomlinson, I. P. M. (2024) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-22-0523 · Cited by 6
Mews, M., Naj, A. C., Griswold, A. J., Below, J. E., & Bush, W. S. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251326288 · Cited by 7
Artificial intelligence in human genomics and biomedicine: Dynamics, potentials and challenges
Heil, R., Heyen, N. B., Baumann, M., Hüsing, B., Bachlechner, D., Schmoch, U., & König, H. (2021) · TATuP - Zeitschrift für Technikfolgenabschätzung in Theorie und Praxis · doi:10.14512/tatup.30.3.30 · Cited by 7
A translational framework of genoproteomic studies for cardiovascular drug discovery
Yang, Z., Zhao, J. V., Qi, Y., Deng, X., Ji, Z., & Liu, J. (2024) · npj Cardiovascular Health · doi:10.1038/s44325-024-00015-9 · Cited by 6
Analytic and Translational Genetics
Karczewski, K. J., & Martin, A. R. (2020) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-072018-021148 · Cited by 7
Identification of Genetic Loci Simultaneously Associated with Multiple Cardiometabolic Traits
Wood, A. C., Arora, A., Newell, M., Bland, V. L., Zhou, J. J., Pirastu, N., Ordovás, J. M., & Klimentidis, Y. C. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.01.002 · Cited by 7
Karim, M. A., Ariano, B., Schwartzentruber, J., Roldán‐Romero, J. M., Mountjoy, E., Hayhurst, J. D., Buniello, A., Mohammed, E. S. E., Carmona, M., Holmes, M. V., et al. (2023) · Research Square · doi:10.1101/2023.06.01.23290252 · Cited by 6
Precision mRNA Nanomedicine for Targeted Vascular Therapies in ARDS and AtherosclerosisPreprint
Zhou, Z., Zhu, J., Yeh, C., Meliton, A. Y., Wu, D., Huang, R., Shentu, T., Ray, A. G., Wiseman, D., Budina, E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.09.632179 · Cited by 8
Chen, N., Gong, L., Zhang, L., Li, Y., Bai, Y., Gao, D., & Zhang, L. (2025) · Biomedicines · doi:10.3390/biomedicines13051022 · Cited by 6
Wang, H., Wang, C., Qin, R., He, J., Zhang, X., Ma, C., Shi, L., Fan, L., Wang, L., & Cao, L. (2025) · Biomedicines · doi:10.3390/biomedicines13061380 · Cited by 7
Bao, C., Gu, L., Wang, S., Zou, K., Zhang, Z., Jiang, L., Chen, L., & Fang, H. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107095 · Cited by 5
Su, Z., & Wan, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1342912 · Cited by 8
Feng, Y., Li, C., Cheng, B., Chen, Y., Chen, P., Wang, Z., Zheng, X., He, J., Zhu, F., Wang, W., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-65 · Cited by 5
Lalagkas, P. N., & Melamed, R. (2024) · Human Genomics · doi:10.1186/s40246-024-00688-4 · Cited by 5
Potential drug targets for asthma identified through mendelian randomization analysis
Chen, X., Shang, Y., Shen, D., Shi, S., Wen, Z., Li, L., & Chen, H. (2025) · Respiratory Research · doi:10.1186/s12931-024-03086-5 · Cited by 6
Wu, X., Wang, K., Li, Q., Zhang, Y., Wei, P., Shan, Y., & Zhao, G. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04700-3 · Cited by 5
The Role of ETS2 in Macrophage Inflammation
Stankey, C. T., & Lee, J. C. (2025) · DNA and Cell Biology · doi:10.1089/dna.2025.0064 · Cited by 5
Mapping the developmental path for Parkinson’s disease therapeutics
Dhruv, N. T., Schwartz, S. R., Swanson‐Fischer, C., Cho, H. J., Corlew, R., Jakeman, L. B., Laboissonniere, L. A., Price, R., Sarraf, S. A., Sieber, B.-A., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01154-1 · Cited by 5
Jalava, N., Kaskinoro, J., Chapman, H., Morales, M., Metsänkylä, H., Heinonen, S., & Koivisto, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043350 · Cited by 5
Mortezaei, Z., Mohammadian, A., & Tavallaei, M. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09910 · Cited by 5
Martin, B. J., Jacob, H. J., Hajduk, P. J., Wolfe, E., Chen, L., Crosby, H., Lefever, M., & Wendell, R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.20.521235 · Cited by 6
UK Biobank: Transforming drug discovery and precision medicine
Bešević, J., Said, S., Nagy, R., Jamshidi, Y., Whelan, C. D., Carson, L., Rutter, M. K., Lewandowski, A. J., Effingham, M., Collins, R., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70254 · Cited by 4
Yuan, Q., Xiong, Z., Zhang, K., Zhang, Q., Zhang, W., & Zhang, H. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad147 · Cited by 4
Casazza, W., Inkster, A. M., Gobbo, G. F. D., Yuan, V., Delahaye, F., Marsit, C. J., Park, Y., Robinson, W. P., Mostafavi, S., & Dennis, J. K. (2024) · iScience · doi:10.1016/j.isci.2024.109047 · Cited by 5
From GWASs toward Mechanistic Understanding with Case Studies in Dermatogenetics
Shen, S., Sobczyk, M. K., Paternoster, L., & Brown, S. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.03.013 · Cited by 4
Wang, F., Zhu, L., Cui, H., Guo, S., Wu, J., Li, A., & Wang, Z. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1404123 · Cited by 4
Xue, Y., Xia, Y., Cheng, D., Shi, T., Mei, P., & Hong, S. (2024) · Journal of Dermatological Treatment · doi:10.1080/09546634.2024.2381763 · Cited by 4
Potential drug targets for osteoporosis identified: A Mendelian randomization study
Zhao, G., Wang, Q., Duan, N., Zhang, K., Zhong, L., Sun, L. D., & Lu, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36566 · Cited by 5
IDENTIFYING DRUG TARGETS FOR SCHIZOPHRENIA THROUGH GENE PRIORITIZATION
Heilbron, K., Kraft, J., Braun, A., Awasthi, S., Panagiotaropoulou, G., Schipper, M., Bell, N. Y., Posthuma, D., Pardiñas, A. F., & Ripke, S. (2024) · Translational Psychiatry · doi:10.1016/j.euroneuro.2024.08.036 · Cited by 4
Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease
Yu, K., Li, W., Long, W., Li, Y., Li, Y., Liao, H., & Liu, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-85338-y · Cited by 4
Chen, L. (2025) · DNA Research · doi:10.1093/dnares/dsaf024 · Cited by 6
Semiparametric efficient estimation of small genetic effects in large-scale population cohorts
Labayle, O., Roskams-Hieter, B., Slaughter, J., Tetley-Campbell, K., van der Laan, M. J., Ponting, C. P., Beentjes, S. V., & Khamseh, A. (2024) · Biostatistics · doi:10.1093/biostatistics/kxaf030 · Cited by 5
Sinniah, E., Mizikovsky, D., Shim, W. J., Chow, C. S. Y., Souilmi, Y., Cheng, F., Zheng, Z., Laurie, J., Foster, M., Shah, S. H., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf971 · Cited by 5
Integrated genomic analysis and CRISPRi implicates EGFR in Alzheimer’s disease risk
Leung, Y. Y., Kuksa, P. P., Carter, L., Cifello, J., Greenfest‐Allen, E., Valladares, O., Boateng, L., Laub, S., Tulina, N. M., Moura, S., et al. (2025) · npj Dementia · doi:10.1038/s44400-025-00049-5 · Cited by 6
Simplifying causal gene identification in GWAS loci
Schipper, M., Ulirsch, J. C., Posthuma, D., Ripke, S., & Heilbron, K. (2026) · PLoS Genetics · doi:10.1371/journal.pgen.1012079 · Cited by 7
Rare and Common Variants in GALNT3 May Affect Bone Mass Independently of Phosphate Metabolism
Hassan, N., Gregson, C. L., Tang, H., van der Kamp, M. W., Leo, P., McInerney-Leo, A. M., Zheng, J., Brandi, M. L., TANG, J. C. Y., Fraser, W. D., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4795 · Cited by 4
DNA and RNA Molecules as a Foundation of Therapy Strategies for Treatment of Cardiovascular Diseases
Rakicevic, L. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082141 · Cited by 4
Gong, Z., Wu, D., Ku, Y., Zou, C., Qiu, L., Hao, X., & Liu, L. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03527-x · Cited by 4
Hubaud, A., & Singh, A. P. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.04.001 · Cited by 4
Lin, T.-Y., Chang, Y.-C., Hsiao, Y., Chien, Y., Jheng, Y.-C., Wu, J.-R., Ching, L., Hwang, D., Hsu, C., Lin, T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115594 · Cited by 5
Association between human blood metabolome and the risk of pre-eclampsia
Ding, Y., Yao, M., Liu, J., Fu, W., Zhu, X., He, Y., Ma, Q., Zhang, C., & Yin, J. (2024) · Hypertension Research · doi:10.1038/s41440-024-01586-x · Cited by 4
McCorrison, J., Girke, T., Goetz, L. H., Miller, R. A., & Schork, N. J. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz206 · Cited by 4
Li, J. H., & Ho, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.22.720113 · Cited by 5
Guo, X. D., Tao, M., Ji, X., Han, M., Shen, Y., Hong, C., Guo, H., Shi, W., & Yuan, H. S. (2024) · Scientific Reports · doi:10.1038/s41598-024-74148-3 · Cited by 3
Deciphering the tissue-specific functional effect of Alzheimer risk SNPs with deep genome annotation
Varathan, P., He, B., He, B., Saykin, A. J., Nho, K. T., & Yan, J. (2024) · BioData Mining · doi:10.1186/s13040-024-00400-1 · Cited by 4
Bi, J., Liu, X., Zhang, J., & Zhao, L. (2025) · Medicine · doi:10.1097/md.0000000000046718 · Cited by 4
Deciphering tissue-specific protein regulation for insights into cardiometabolic disease
Hartley, A. E., Sukhavasi, K., Hu, S., Traylor, M., González-Ramírez, M., Hanghøj, K., Talukdar, H. A., Ruusalepp, A., Björkegren, E., Björkegren, J., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102314 · Cited by 3
Mechanisms of inflammatory bowel diseases: Insights from human genetics and chemical biology
Graham, D. B., & Xavier, R. J. (2026) · Immunity · doi:10.1016/j.immuni.2026.04.002 · Cited by 4
Primary atopic disorders: Monogenic insights into immunity
Modi, B. P., McDonald, C., Golding, L., da Silva, L. B. R., Biggs, C. M., Körholz, J., James, E. L., & Turvey, S. E. (2026) · Journal of Human Immunity · doi:10.70962/jhi.20260006 · Cited by 3
Tamaki, R., Kogai, H., Sagane, K., Aoshima, K., & Li, S. D. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01149 · Cited by 3
The Role of Genetics in Advancing Cardiometabolic Drug Development
Abou-Karam, R., Cheng, F., Gady, S., & Fahed, A. C. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01195-6 · Cited by 4
IBDTransDB: a manually curated transcriptomic database for inflammatory bowel disease
Avram, V., Yadav, S., Sahasrabudhe, P., Chang, D., & Wang, J. (2024) · Database · doi:10.1093/database/baae026 · Cited by 3
Londoño-Correa, D., de la Fuente, J., Davies, G., Cox, S. R., Deary, I. J., Harden, K. P., & Tucker–Drob, E. M. (2026) · Nature Communications · doi:10.1038/s41467-026-72477-7 · Cited by 5
Elenbaas, J. S., Lee, P. C., Patel, V., & Stitziel, N. O. (2025) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061724-080905 · Cited by 3
Tian, T., Han, H., Huang, J., Ma, J., & Ran, R. (2025) · Biomedicines · doi:10.3390/biomedicines13051115 · Cited by 4
Wray, J., & Whitmore, A. V. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1787-8_7 · Cited by 3
Genetic Pleiotropy of Bone-Related Phenotypes: Insights from Osteoporosis
Christou, M., Ntzani, E., & Karasik, D. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00618-y · Cited by 3
Single Nucleotide Polymorphisms: Human Variation and a Coming Revolution in Biology and Medicine
(2022) · Springer eBooks · doi:10.1007/978-3-031-05616-1 · Cited by 6
A resource for integrated genomic analysis of the human liver
Zhou, Y., Gallins, P. J., Etheridge, A. S., Jima, D. D., Scholl, E. H., Wright, F. A., & Innocenti, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-18506-z · Cited by 3
Preclinical target validation for non-addictive therapeutics development for pain
Hargreaves, R. J., Akinsanya, K., Ajit, S. K., Dhruv, N. T., Driscoll, J., Farina, P., Gavva, N. R., Gill, M., Houghton, A. K., Iyengar, S., et al. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2147063 · Cited by 3
Identifying Genes Associated with Alzheimer’s Disease Using Gene-Based Polygenic Risk Score
Lai, D., Zhang, M., Li, R., Zhang, C., Zhang, P., Liu, Y., Gao, S., & Foroud, T. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230510 · Cited by 3
Lessons From The Glaucoma Foundation Think Tank 2023: A Patient-Centric Approach to Glaucoma
Harris, A., Vercellin, A. C. V., Weinreb, R. N., Khawaja, A. P., MacGregor, S., & Pasquale, L. R. (2023) · Journal of Glaucoma · doi:10.1097/ijg.0000000000002353 · Cited by 3
Shared etiology of Mendelian and complex disease supports drug discovery
Lalagkas, P. N., & Melamed, R. (2024) · BMC Medical Genomics · doi:10.1186/s12920-024-01988-3 · Cited by 4
Integrative Analyses of Transcriptomes to Explore Common Molecular Effects of Antipsychotic Drugs
Truong, T. T. T., Bortolasci, C. C., Kidnapillai, S., Spolding, B., Panizzutti, B., Liu, Z. S.-J., Kim, J. H., Dean, O. M., Richardson, M. F., Berk, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147508 · Cited by 4
Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer’s Disease
Nabirotchkin, S., Bouaziz, J., Glibert, F., Mandel, J., Foucquier, J., Hajj, R., Callizot, N., Cholet, N., Guedj, M., & Cohen, D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220120 · Cited by 2
Zuckerman, B. P., Yang, Z., Warwick, A., Wincup, C., Russell, M., Galloway, J. B., & Zhao, S. S. (2024) · Rheumatology · doi:10.1093/rheumatology/keae475 · Cited by 2
Shook, M., Lu, X., Chen, X., Edsall, L., Granitto, M., Virolainen, S. J., Forney, C. R., Donmez, O. A., Parameswaran, S., Fadden, C., et al. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.07.032 · Cited by 3
Dang, C., Wu, Q. F., Pan, J., Yu, X., Liu, J., Liu, P., & Wang, Y. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s530521 · Cited by 2
Yu, Z., Qian, F., Fang, Q.-L., Meng, X., Li, Y., Feng, C., Li, L., Li, B., Feng, Y.-R., Jiang, H., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1112 · Cited by 2
Richardson, T. I., Klein, R. C., Huang, K., Zhang, J., Mesecar, A. D., Dage, J. L., Clayton, B., Lamb, B. T., & Palkowitz, A. D. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.70964 · Cited by 2
From GWAS Signals to Causal Genes in Chronic Kidney Disease
Delrue, C., Speeckaert, R., & Speeckaert, M. M. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48020148 · Cited by 3
From correlation to causation: cell‐type‐specific gene regulatory networks in Alzheimer's disease
Liu, D., Jiang, Z., Kim, H., Tukker, A. M., Dalvi, A., Xie, J., Li, Y., Yuan, C., Bowman, A. B., Zhang, D., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71053 · Cited by 2
Pharmacogenomics and genetic ancestry: an opportunity to transform clinical practice in Colombia
Acosta-Monterrosa, A. A., Montoya-Quintero, K. F., Barceló-Martinez, E., & Galván-Barrios, J. P. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1774562 · Cited by 2
Sobczyk, M. K., & Gaunt, T. R. (2026) · Scientific Reports · doi:10.1038/s41598-026-41818-3 · Cited by 3
Metadata
- Authors
- King, E. A., Davis, J. W., & Degner, J. F.
- Affiliations
- AbbVie (United States) (US)
- Corresponding author
- King, Emily A.
- Venue
- PLOS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-12-12
- Volume
- 15
- Issue
- 12
- Pages
- e1008489
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- PMC
- PMC6907751
- OpenAlex
- W2995245946
- Cited by
- 649
- References
- 40
- Citations by year
- 2026: 71 · 2025: 97 · 2024: 132 · 2023: 118 · 2022: 92 · 2021: 85 · 2020: 47 · 2019: 6
- FWCI
- 34.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Genetics (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- drug approval, therapeutic target, genetic evidence, drug development pipeline, new chemical entities, monogenic disorders, genome-wide association study, coding variants, drug development investment
- MeSH terms
- Pharmacogenomic Variants, Humans, Phenotype, Models, Statistical, Drug Approval, Genetic Predisposition to Disease, Genomics, Databases, Genetic, Quantitative Trait Loci, Genome-Wide Association Study, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.